I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

Guy's is one of the first hospitals in the country to roll out weight-loss jabs. But whilst millions across the ...

Ozempic and Wegovy have become popular options for people looking to lose weight, but there are some risks and side effects ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...